Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus (Q37924980)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 August 2011

Language	Label	Description	Also known as
English	Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus	scientific article published on 23 August 2011

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus (English)

1 reference

Europe PubMed Central

25 August 2017

methicillin-resistant Staphylococcus aureus

0 references

antibiotic resistance

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

Andreas Ambrosch

1

1 reference

Europe PubMed Central

25 August 2017

Simone Haefner

2

1 reference

Europe PubMed Central

25 August 2017

Edward Jude

3

1 reference

Europe PubMed Central

25 August 2017

Ralf Lobmann

4

1 reference

Europe PubMed Central

25 August 2017

publication date

23 August 2011

1 reference

Europe PubMed Central

25 August 2017

International Wound Journal

1 reference

Europe PubMed Central

25 August 2017

8

1 reference

Europe PubMed Central

25 August 2017

567-577

1 reference

Europe PubMed Central

25 August 2017

6

1 reference

Europe PubMed Central

25 August 2017

The diabetic foot: grand overview, epidemiology and pathogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Problem of amputations in patients with newly diagnosed diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Long-term prognosis for diabetic patients with foot ulcers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Costs of type 2 diabetes in Germany. Results of the CODE-2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Assessment and management of foot disease in patients with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Infections and diabetes: mechanisms and prospects for prevention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Identification and biochemical characterization of the ligand binding domain of the collagen adhesin from Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

A low-fibronectin-binding mutant of Staphylococcus aureus 879R4S has Tn918 inserted into its single fnb gene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Slime production by Staphylococcus aureus and Staphylococcus epidermidis strains isolated from patients with diabetic foot ulcers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Why chronic wounds will not heal: a novel hypothesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Small colony variants in staphylococcal infections: diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers: a new paradigm

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Country-to-country transfer of patients and the risk of multi-resistant bacterial infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Epidemiology of diabetic foot problems and predictive factors for limb loss.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-481X.2011.00849.X

21 January 2018

Identifiers

10.1111/J.1742-481X.2011.00849.X

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37924980&oldid=1784398945"